Genfit S.A. – NASDAQ:GNFT
Founder-led company
Genfit S.A. stock price today
$4.32
+0.62
+16.76%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Genfit S.A. stock price monthly change
-12.94%
month
Genfit S.A. stock price quarterly change
-12.94%
quarter
Genfit S.A. stock price yearly change
-5.13%
year
Genfit S.A. key metrics
Market Cap | 189.47M |
Enterprise value | N/A |
P/E | 2.50 |
EV/Sales | -8.84 |
EV/EBITDA | 0.82 |
Price/Sales | 51.14 |
Price/Book | 1.14 |
PEG ratio | 0.01 |
EPS | -0.87 |
Revenue | 38.93M |
EBITDA | -41.84M |
Income | -43.34M |
Revenue Q/Q | 180.27% |
Revenue Y/Y | 48.24% |
Profit margin | -991.23% |
Oper. margin | -928.87% |
Gross margin | 100% |
EBIT margin | -928.87% |
EBITDA margin | -107.47% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGenfit S.A. stock price history
Genfit S.A. stock forecast
Genfit S.A. financial statements
| Mar 2023 | 7.55M | -10.42M | -138% |
|---|---|---|---|
| Jun 2023 | 11.48M | -20.85M | -181.62% |
| Sep 2023 | 2.81M | -4.01M | -142.65% |
| Dec 2023 | 17.08M | -8.03M | -47.06% |
| 2025 | 44.41M | -19.42M | -43.73% |
|---|---|---|---|
| 2026 | 89.12M | 21.78M | 24.44% |
| 2027 | 121.79M | 68.89M | 56.57% |
| 2028 | 186.15M | 105.49M | 56.67% |
Analysts Price target
Financials & Ratios estimates
| Apr 2023 | 193905000 | 119.38M | 61.57% |
|---|---|---|---|
| Jun 2023 | 193905000 | 119.38M | 61.57% |
| Sep 2023 | 173872000 | 105.92M | 60.92% |
| Dec 2023 | 173342000 | 105.92M | 61.11% |
| Mar 2023 | -12.53M | 1.34M | -882K |
|---|---|---|---|
| Jun 2023 | -25.84M | 2.68M | -995K |
| Sep 2023 | -15.17M | -224K | -1.66M |
| Dec 2023 | -30.07M | -448K | -3.61M |
Genfit S.A. alternative data
| Aug 2023 | 148 |
|---|---|
| Sep 2023 | 148 |
| Oct 2023 | 154 |
| Nov 2023 | 154 |
| Dec 2023 | 154 |
| Jan 2024 | 154 |
| Feb 2024 | 154 |
| Mar 2024 | 154 |
| Apr 2024 | 154 |
| May 2024 | 159 |
| Jun 2024 | 159 |
| Jul 2024 | 159 |
Genfit S.A. other data
0.00%
-0.00%
of GNFT is owned by hedge funds
233.53K
-1.92M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2021 8 Apr 2022 | Q4 2021 Earnings Call Transcript |
| Q2 2020 1 Oct 2020 | Q2 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. M. Pascal Prigent (1968) Chief Executive Officer | $468,560 |
Mr. Jean-Francois Mouney (1955) Co-Founder & Chairman | $274,560 |
Genfit: Under The Radar Biotech With Upcoming Catalysts
Gilead Sciences: Seriously Undervalued At Peak Pessimism
Genfit: Large PBC Market, Liquidity To Await Approval
CymaBay: Positive Phase 3 Data And Competitive Advantage Established
Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling
Genfit: Catching Strong Bid With Emerging Data (Technical Analysis)
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma
Genfit S.A.: A 'Sum Of The Parts' Story
Madrigal: Clear Path Ahead
-
What's the price of Genfit S.A. stock today?
One share of Genfit S.A. stock can currently be purchased for approximately $4.32.
-
When is Genfit S.A.'s next earnings date?
Unfortunately, Genfit S.A.'s (GNFT) next earnings date is currently unknown.
-
Does Genfit S.A. pay dividends?
No, Genfit S.A. does not pay dividends.
-
How much money does Genfit S.A. make?
Genfit S.A. has a market capitalization of 189.47M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 41.45% to 28.57M US dollars.
-
What is Genfit S.A.'s stock symbol?
Genfit S.A. is traded on the NASDAQ under the ticker symbol "GNFT".
-
What is Genfit S.A.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Genfit S.A.?
Shares of Genfit S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Genfit S.A.'s key executives?
Genfit S.A.'s management team includes the following people:
- Mr. M. Pascal Prigent Chief Executive Officer(age: 57, pay: $468,560)
- Mr. Jean-Francois Mouney Co-Founder & Chairman(age: 70, pay: $274,560)
-
Is Genfit S.A. founder-led company?
Yes, Genfit S.A. is a company led by its founder Mr. Jean-Francois Mouney.
-
How many employees does Genfit S.A. have?
As Jul 2024, Genfit S.A. employs 159 workers, which is 3% more then previous quarter.
-
When Genfit S.A. went public?
Genfit S.A. is publicly traded company for more then 6 years since IPO on 27 Mar 2019.
-
What is Genfit S.A.'s official website?
The official website for Genfit S.A. is genfit.com.
-
How can i contact Genfit S.A.?
Genfit S.A. can be reached via phone at +33 3 20 16 40 00.
Genfit S.A. company profile:
Genfit S.A.
genfit.comExchange:
NASDAQ
Full time employees:
169
Industry:
Biotechnology
Sector:
Healthcare
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Parc EurasantE
Loos, 59120
Loos, 59120
CIK: 0001757064
ISIN: US3722791098
CUSIP: 372279109
